GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity.
The term “prescription cannabinoid” refers to products containing one or more marijuana plant-derived or synthetically manufactured cannabinoids that are available by prescription only. Currently, in the U.S. only three prescription cannabinoids are FDA-approved and legal to be prescribed in all states. These include:
Cesamet (nabilone, a synthetic cannabinoid similar to THC) – Available in the U.S.
Epidiolex (a plant-derived CBD) – Available in the U.S.
Marinol (dronabinol, a synthetic THC) – Available in the U.S.
Sativex (a combination of THC and CBD in a 1:1 ratio) is a prescription cannabinoid available in Canada and Europe but not yet FDA-approved or available in the U.S. Some of the most informative research into medical uses of marijuana has come from studies evaluating Sativex because it is plant-based and contains both THC and CBD as well as other pharmacologically significant cannabis plant constituents including some terpenes.
ABOUT ARBOR VITA8: Arbor Vita8 is a seed-to-sale commercial hemp company operating out of a 75,000 sq ft facility in Phenix City, Alabama. As the leading resource for licensed hemp seed sales, cultivation, processing and wholesaling, Arbor Vita8 is focused on helping our farming and manufacturing partners thrive. Visit https://arborvita8.com for more information.